

1 **Title page:**

2 **Title:**

3 Fear of COVID-19 after vaccination dissemination and its relationship with multidimensional
4 health literacy among patients on maintenance haemodialysis

5

6 **Authors:**

7 Atsuro Kawaji^{1#}, Ryohei Inanaga^{2, 3#}, Mamiko Ukai^{4#}, Tetsuro Aita^{2, 5}, Yusuke Kanakubo^{4, 6},
8 Takumi Toishi¹, Masatoshi Matsunami^{1, 2}, Tatsunori Toida^{2, 7}, Yu Munakata^{8, 9}, Tadao
9 Okada⁴, Tomo Suzuki^{1, 2}, Noriaki Kurita^{2, 10}

10 [#]AK, RI, and MU contributed equally.

11

12 **Affiliations:**

13 ¹Department of Nephrology, Kameda Medical Center, Chiba, Japan

14 ²Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical
15 University, Fukushima, Japan

16 ³Department of Nephrology, Shin-Yurigaoka General Hospital, Kanagawa, Japan

17 ⁴Tessyoukai Kameda Family Clinic Tateyama, Chiba, Japan

18 ⁵Department of General Internal Medicine, Fukushima Medical University Hospital,
19 Fukushima, Japan

20 ⁶Division of Clinical Epidemiology, Research Center for Medical Sciences, The Jikei University
21 School of Medicine, Tokyo, Japan

22 ⁷School of Pharmaceutical Sciences, Kyushu University of Health and Welfare, Miyazaki,
23 Japan

24 ⁸Chikuseikai Munakata Clinic, Tokyo, Japan

25 ⁹Munakata Clinic, Chiba, Japan

26 ¹⁰Department of Innovative Research and Education for Clinicians and Trainees (DiRECT),
27 Fukushima Medical University Hospital, Fukushima, Japan

28

29 **Correspondence to:**

30 Tomo Suzuki, MD, PhD

31 Department of Nephrology

32 Kameda Medical Center

1 929, Higashicho, Kamogawa, Chiba 296-8602, Japan

2 Phone: +81-4-7092-2211

3 Email: suzuki.tomo@kameda.jp

4 ORCID: 0000-0001-5536-1741

5 X handle: [km_nephrology](#)

6

7 **Word count:** 2699 words

8 **Number of figures, tables, boxes, references:** 4

9 **Running head:** health literacy and COVID-19 fear

1 **Abstract**

2 **Background and hypothesis.**

3 The increased anxiety owing to the COVID-19 pandemic has been suggested to contribute to
4 unhealthy lifestyles and depression in patients undergoing haemodialysis (HD). Therefore,
5 this study aimed to evaluate the degree of fear of COVID-19 after vaccination dissemination
6 and the independent impact of high-order health literacy (HL) on fear, which have not been
7 adequately investigated.

8 **Methods.**

9 This multicentre cross-sectional study, conducted in 2022, after the widespread availability
10 of the COVID-19 vaccination in Japan, included adults undergoing in-centre HD.

11 Multidimensional HL was measured using the 14-item Functional, Communicative, and
12 Critical Health Literacy Scale. Fear of COVID-19 was measured using the 7-item Japanese
13 version of the Fear of COVID-19 Scale. COVID-19 fear scores in patients with HD were
14 compared with scores of adults in April 2020 (the beginning of the pandemic) using an
15 unpaired t-test. The association between multidimensional HL and COVID-19 fear scores
16 was estimated using a multivariable-adjusted general linear model.

17 **Results.**

18 A total of 446 patients were analysed, of whom 431 (97%) and nine (2%) received three and
19 two doses of vaccination, respectively. Their COVID-19 fear scores were significantly lower
20 than those of the general population at the beginning of the pandemic ($p < 0.001$; mean
21 difference -4.4 [95% confidence interval (CI): -5.1 – -3.7]; standardised effect size [ES] 0.77).
22 Higher functional HL was associated with less fear (per 1-pt higher: -2.8 [95% CI: -1.7 – -0.3];
23 standardised ES -0.51), whereas higher critical HL was associated with greater fear (per 1-pt

1 higher: 3.2 [95% CI: 0.7 – 3.0]; standardised ES 0.80). Communicative HL was not associated
2 with fear.

3 **Conclusion.**

4 Patients' fear of low-functional HL, despite widespread vaccination, can be reduced by
5 providing health information in an easy-to-understand manner. Thus, the fear of sceptics
6 owing to excessive critical HL and honest explanations by healthcare providers may be
7 important.

8

9 **Key learning points**

10 **What was known:**

11 Heightened anxiety stemming from the COVID-19 pandemic exacerbates unhealthy
12 lifestyles and depression, particularly in patients undergoing haemodialysis.

13 Health literacy plays a crucial role in individuals with kidney disease and may mitigate
14 anxiety.

15 Comprehensive data on whether multidimensional health literacy (functional, critical, and
16 communicative) independently correlates with fear of COVID-19, particularly in the context
17 of patients undergoing haemodialysis are lacking.

18 **This study adds:**

19 COVID-19 fear scores were notably lower in patients undergoing haemodialysis who
20 received the COVID-19 vaccination than in the general population at the onset of the
21 pandemic.

22 Elevated functional health literacy correlated with reduced fear, whereas higher critical
23 health literacy was linked to increased fear.

1 **Potential impact:**

2 Fear among individuals with low functional health literacy can be alleviated by delivering
3 health information in a clear and accessible manner, whereas transparent and honest
4 communication from healthcare providers is crucial for patients with heightened fear owing
5 to critical health literacy, who may be sceptical of accurate information.

6

7 **Keywords:** COVID-19, health literacy, anxiety, haemodialysis, end-stage kidney disease.

1 Introduction

2 Fear of the COVID-19 pandemic causes considerable anxiety disorders, especially
3 among patients with chronic kidney disease (CKD) who are at high risk of severe disease. In
4 particular, patients undergoing haemodialysis who are required to share a specific space
5 and spent time in a dialysis unit would have felt strong fear during epidemic periods.
6 Although strong fear and anxiety may have increased adherence to vaccination and wearing
7 of masks in public places, they have also been suggested to have contributed to unhealthy
8 lifestyle habits, weight gain, isolation, and depression among patients with CKD (1,2).
9 Considering the potentially increased risk of all-cause mortality and 1-year hospitalisation
10 rates associated with anxiety symptoms (3), the identification of related factors and
11 implementation of measures to mitigate fear is clinically important. Health literacy (HL), or
12 the ability to understand, discern, or use appropriate information, may help mitigate anxiety
13 because patients with CKD are likely to be confused by inconsistent information about
14 COVID-19 (2). Consequently, HL was viewed as a social vaccine that empowered people to
15 protect their own and high-risk populations' health during the COVID-19 pandemic (4).
16 Given that many patients with CKD have low HL (5), examining the impact of HL on fear of
17 COVID-19 is important; however, it remains poorly studied.

18 Although one study showed that low HL was associated with high anxiety among
19 patients with preserved CKD (1), only “conventional” HL was assessed. Recently, however,
20 the importance of assessing multidimensional HL has increased (6,7). That is, in addition to
21 the most basic functional HL, such as reading and writing, communicative HL (i.e., the ability
22 to extract information, infer meaning, and apply information to changing situations) and
23 critical HL (i.e., the ability to critically analyse information and control current situations) are

1 also gaining attention (6). One small study showed that higher levels of each of these
2 multidimensional HL dimensions correlated with lower levels of COVID-19 anxiety among
3 patients undergoing haemodialysis. However, the study failed to examine how individual
4 dimensions independently affected anxiety about COVID-19, even though each of the HL
5 dimensions was correlate with the others (8). Therefore, identifying the dimensions of HL
6 that independently influence the fear of COVID-19 in patients undergoing haemodialysis
7 would be useful in developing support tailored to their individual health literacy.
8 Furthermore, the potential to identify and address patients with excessive fear persists
9 despite the spread of effective measures against COVID-19, such as vaccines.

10 Therefore, we aimed to quantify the degree of fear of COVID-19 among patients
11 undergoing maintenance haemodialysis after vaccine dissemination and evaluate whether
12 multidimensional HL (functional, critical, and communicative) was independently associated
13 with fear of COVID-19.

14

15 **Materials and Methods**

16 *Study Design and Participants*

17 This multicentre cross-sectional study was conducted at six medical institutions
18 providing outpatient haemodialysis: Kameda Medical Center (Chiba), Kameda Family Clinic
19 Tateyama (Chiba), Awa Regional Medical Center (Chiba), Munakata Clinic (Chiba),
20 Chikuseikai Munakata Clinic (Tokyo), and Shinyurigaoka General Hospital (Kanagawa). The
21 participants were adult patients with End-stage kidney disease (ESKD) who regularly visited
22 the participating facilities and received either haemodialysis or a hybrid treatment of
23 haemodialysis and peritoneal dialysis. Patients deemed by medical staff as unable to

1 respond to the study questionnaire by themselves were excluded from the study. A paper-
2 based questionnaire was distributed at each facility, and the participants were asked to
3 complete the questionnaire at home and return it to the medical staff without identifying
4 the content. The respondents were provided with a 500-yen gift card as an incentive. In
5 addition, the attending physician extracted dialysis-related patient data from medical
6 records. Data were collected between June 2022 and February 2023, after the spread of the
7 COVID-19 vaccine in Japan. This study was conducted in accordance with the Declaration of
8 Helsinki and approved by the Institutional Review Board of Fukushima Medical University
9 (approval number: ippan2021-292). All participants were provided with information about
10 the study in advance, and written informed consent was obtained from all participants.

11

12 *Measures*

13 *Outcome: Fear of COVID-19*

14 The main outcome, fear of COVID-19, was measured using the Japanese version of
15 the COVID-19 Scale (9,10). This scale consists of seven items and responses are scored on a
16 5-point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). The total score
17 was calculated by adding the scores for each item (7–35 points), with a higher score
18 indicating a stronger fear of COVID-19. The Japanese version of the scale has been validated
19 in the general population and has been confirmed to have internal consistency reliability (α
20 = 0.87) and validity (9).

21

22

1 *Exposure: multidimensional health literacy*

2 The main exposure, multidimensional HL, was measured using the Functional,
3 Communicative, and Critical Health Literacy (FCCHL) scale (11). This self-report scale consists
4 of 14 items and can be scored on three subscales: Functional HL (five items), Communicative
5 HL (five items), and Critical HL (four items). Responses to each item were scored on a four-
6 point Likert scale ranging from 1 (never) to 4 (often). The scores were reversed when
7 functional HL was measured. The mean score of the corresponding items was used as the
8 scale score for each of the three subscales, with higher scores indicating higher HL levels of
9 health literacy. This scale has previously shown high internal consistency for functional,
10 communicative, and critical HL (alpha coefficients of 0.84, 0.77, and 0.65, respectively) in
11 Japanese patients with type 2 diabetes, demonstrating its construct validity and reliability
12 (11).

13

14 *Measurement of Covariates*

15 Based on the literature and expert knowledge, potential confounding factors that
16 could affect health literacy and fear of COVID-19 were identified. The covariates included
17 age, sex, duration of dialysis, smoking history, educational level, household income, and
18 comorbidities. Comorbidities were scored based on the modified Charlson Comorbidity
19 Index (CCI) for patients undergoing dialysis (12,13).

20

21

22

1 *Statistical Analyses*

2 Statistical analyses were performed using Stata/SE, version 17 (StataCorp, College
3 Station, TX, USA). Patient characteristics are presented as median and interquartile range
4 (IQR) for continuous variables and as frequencies and percentages for categorical variables.
5 Differences between the fear of COVID-19 scores in the present study and those of 450
6 Japanese adults in April 2020 (i.e. the beginning of the COVID-19 pandemic) reported in the
7 development paper were compared using an unpaired t-test (9). The association between
8 the aforementioned covariates and each domain of multidimensional HL was estimated
9 using general linear models. Subsequently, the association between multidimensional HL
10 and fear of COVID-19 was estimated using a general linear model. The above-mentioned
11 covariates were adjusted. All models were estimated using robust standard errors to
12 address heteroscedasticity. We assumed that the data analysed were missing at random,
13 and imputed the missing data using multiple imputations with chained equations to perform
14 20 imputations (14). A two-sided significance level of $p < 0.05$ was used for each analysis.

15

16 **Results**

17 *Study flow and patient characteristics*

18 Among the 651 patients undergoing haemodialysis at six facilities, 484 (74.3%)
19 participated in the study. After excluding 38 cases with missing data on the fear of COVID-
20 19, 446 cases were analysed. Patient characteristics are shown in Table 1. The median age
21 of the patients was 69 years (IQR 63–78), and 157 (35.2%) patients were women. A total of
22 61.6% patients had graduated from high school and 79.8% patients had a household income
23 of < 5 million yen. A total of 431 (96%) and nine (2%) patients received three and two doses

1 of the COVID-19 vaccine, respectively. The median scores for the functional, communicative,
2 and critical HL subdomains were 3.2 (IQR 2.6–3.8), 2.8 (IQR 2.2–3.2), and 2.5 (IQR 2.0–3.0),
3 respectively.

4

5 *Comparison of the fear of COVID-19 between study participants and the general population*
6 *in the early phase of the pandemic*

7 The mean and standard deviation of the fear of COVID-19 scores among the
8 participants was 16.9 and 5.7 points, which was significantly lower than the score of the
9 general population in the early phase of the pandemic ($p < 0.001$; mean difference -4.4 [95%
10 confidence interval (CI): -5.1 to -3.7]; standardised effect size (ES) 0.77). (9) (Figure 1):

11

12 *Association between HL subdomains and patient characteristics*

13 Table 2 shows the association between the HL subdomains and covariates.
14 Functional HL was positively associated with dialysis duration (per 1 year higher: 0.01 [95%
15 CI: 0.002 – 0.02]) and education (especially high school, university, and other) (vs. junior
16 high school or lower: 0.37 [95% CI: 0.16 – 0.58], 0.64 [95% CI: 0.39 – 0.89], 0.87 [95% CI:
17 0.27 – 1.46]) but negatively associated with comorbidity score (per 1 point higher: -0.66
18 [95% CI: -0.11 – -0.02], respectively). Communicative HL was positively associated with
19 educational level (especially university graduate, high school, other) (vs. junior high school
20 or lower: 0.50 [95% CI: 0.27 – 0.74], 0.17 [95% CI: 0.0004 – 0.34], 0.63 [95% CI: 0.07 – 1.12],
21 respectively) and was negatively associated with age (per 1 year higher: -0.07 [95% CI: -0.12
22 – -0.002]) and comorbidity score (per 1 point higher: -0.05 [95% CI: -0.08 – -0.01]). Critical

1 HL was positively associated with educational level (especially university graduate, other) (vs.
2 junior high school or lower: 0.46 [95% CI: 0.21 – 0.71], 0.58 [95% CI: 0.07 – 2.20]) but
3 negatively associated with comorbidity score (per 1-point higher: -0.04 [95% CI: -0.07 – -
4 0.006]).

5

6 *Association between fear of COVID-19 and multidimensional HL*

7 Table 3 shows the associations among fear of COVID-19 and HL subdomains, and
8 covariates. Fear of COVID-19 was negatively associated with functional HL (per 1-point
9 higher: -0.99 [95% CI: -1.72 – -0.26]) and household income (especially > 5 million yen – < 10
10 million yen) (reference: < 1 million yen: -3.01 [95% CI: -5.41 – -0.61]). In contrast, higher
11 critical HL (per 1-point higher: 1.85 [95% CI: 0.74 – 2.97]) and women (vs. men; 1.98 [95% CI:
12 0.73 – 3.23]) were positively associated with fear of COVID-19. Communicative HL was not
13 associated with fear.

14

15 **Discussion**

16

17 Our results indicated that fear of COVID-19 among adult Japanese patients on
18 haemodialysis was significantly lower than that of the general population in the early phase
19 of the pandemic after the widespread distribution of the COVID-19 vaccine. However, the
20 findings that low functional HL and high critical HL were associated with increased fear of
21 COVID-19 highlight the need for measures tailored to individual HL even after the
22 dissemination of the vaccine.

1 Although previous research on the level of anxiety after the widespread use of
2 COVID-19 vaccines among patients on dialysis is scarce, findings on the relationship
3 between multidimensional HL and COVID-19-related anxiety are similar to those found in
4 the non-dialysis population. Older age and a history of diabetes, heart disease, or lung
5 disease were associated with an increased likelihood of having anxiety related to COVID-19
6 in a study conducted on the general population in the UK during the early period of the
7 COVID-19 pandemic (March 2020) (15). There are a few possible reasons why our patients
8 with the same serious illness as those mentioned above were less anxious about COVID-19
9 than the general population before the pandemic. First, the high vaccination rate (98%) and
10 alleviation of uncertainty regarding the pathogenesis and prevention of COVID-19 in the
11 early phase of the pandemic may have reduced anxiety in our study participants. Similarly,
12 although patients on haemodialysis were more anxious than those on peritoneal dialysis
13 before the vaccination programme in a study comparing patients on haemodialysis and
14 peritoneal dialysis in the Netherlands, no such difference was observed after the
15 programme (16). However, as noted in a previous synthesised qualitative study, the
16 uncertainty about healthcare experienced during the pandemic, such as the disruption of
17 care, confusion owing to a lack of reliable information, and scepticism about vaccines,
18 undoubtedly contributed to anxiety among patients on dialysis (2).

19 Another explanation is that the mental health of patients on dialysis was resilient to
20 or unaffected by the COVID-19 pandemic. This is consistent with a previous study wherein
21 mental health was not affected during the pandemic in Dutch patients with CKD or in those
22 on dialysis who did not develop COVID-19 (17). Additionally, the limited impact of social
23 distancing measures compared to that in the general population (18), the strengthening of

1 family ties, and the sense of safety towards healthcare institutions owing to strict
2 preventative measures (2,18) may have helped alleviate anxiety.

3 A U.S. study on fear of COVID-19 linked to low health literacy among patients with
4 non-dialysis-dependent CKD only examined functional HL (1). Whereas, all three types of
5 HLs (functional, communicative, and critical) showed a negative correlation (i.e. low health
6 literacy was associated with a high fear of COVID-19) with fear of COVID-19 among patients
7 on haemodialysis (8); however, this study did not adjust for confounding factors. In contrast,
8 as shown in the current study, differences owing to confounding factors such as age, sex,
9 education history, and comorbidities were not addressed. Additionally, although our finding
10 of higher critical HL along with a greater fear of COVID-19 contradicts the Korean study; it is
11 consistent with a survey of the Japanese general population (19). The fear of COVID-19
12 among groups with high HL in that study was also directed toward government and social
13 policies. (19) Moreover, higher critical HL has been suggested to be associated with worse
14 medication adherence (particularly in terms of behavioural aspects) among patients on
15 haemodialysis, mainly owing to a loss of trust in physicians (7). Additionally, patients with
16 high critical HL may have gathered too much information about the pandemic resulting in
17 unnecessary scepticism about the gathered information, including the best information
18 provided by the government and physicians at the time.

19 This study has several clinical implications for dialysis providers. First, communicating the
20 correct medical information about COVID-19 using plain language in an easy-to-understand
21 manner is important for patients with low functional HL. For example, the term “droplet
22 infection” as a medical term is difficult to understand, however explaining “it is an infection
23 that occurs when the virus is scattered from the mouth when talking” is easier to

1 understand. In addition, providing visual aids to communicate recommended preventive
2 measures, such as wearing masks, will encourage preventive behaviours. Second, for
3 patients with excessively high critical HL, we should consider the positive aspect that
4 caution provides opportunities for appropriate preventive actions. Therefore, dialysis
5 physicians must support patients by identifying misleading information, false claims, and
6 fake news (4). For example, although measures against COVID-19 from reliable information
7 sources (e.g. government or medical institutions) are likely to be beneficial, a claim by a
8 Japanese academic virologist about the risk of miscarriage owing to COVID-19 vaccination
9 via social media may have been difficult to discern as false without comparing different
10 sources or checking for evidence of its origin. Finally, doctors need to be aware of the kinds
11 of patients who are likely to have low functional or high critical HL. In this study, low
12 functional HL was associated with a high number of comorbidities, low educational level,
13 and shorter dialysis duration. In contrast, high critical HL was associated with younger age,
14 low number of comorbidities, and high education level. Thus, addressing individual HL is
15 important because it is affected by several common factors such as education level and
16 comorbidities.

17 The strengths of this study include the relatively high participation rate and multi-
18 centre design, making the results highly generalisable. In addition, we analysed the
19 association between multidimensional HL and fear of COVID-19 after adjusting for relevant
20 confounding factors. Nonetheless, this study has some limitations. First, although this study
21 measured general HL, it did not directly assess HL related to COVID-19. Second, because this
22 was a cross-sectional study, a possibility of reverse causation exists. For example, it is
23 possible that patients were fearful of COVID-19 and, therefore, were sceptical of health
24 information, including correct information. Third, because most patients had already been

1 vaccinated, we were unable to compare their HL or fear of COVID-19 with those who had
2 not been vaccinated.

3 In conclusion, fear of COVID-19 among adult Japanese patients undergoing
4 haemodialysis after the widespread COVID-19 vaccine was lower than that in the general
5 population at the beginning of the pandemic. The fear of COVID-19 in patients with low-
6 functional HL can be reduced by providing health information in an easy-to-understand
7 manner. Consequently, honest explanations by healthcare providers may be important for
8 patients with scepticism about correcting information and a strong fear of excessive critical
9 HL. This study is novel in that it investigated the degree of fear of COVID-19 following
10 vaccination and the independent influence of multidimensional HL on fear. An
11 understanding of individual HL may help them to provide appropriate anxiety reduction
12 measures for future pandemics.

13

14 **Data availability statement:**

15 The datasets generated and/or analysed in the current study are available from the
16 corresponding author upon reasonable request.

17

18 **Acknowledgements:**

19 The authors greatly thank the following researchers, research assistants, and medical staff
20 members for their assistance in collecting the questionnaire-based and clinical information
21 used in this study: Ms. Aki Tairaku (Shin-Yurigaoka General Hospital, Kawasaki-City,
22 Kanagawa); Ms. Takako Saruwatari and Ms. Akiko Kamimura (Kyushu University of Health
23 and Welfare, Nobeoka-City, Miyazaki); Tetuo Ueki, MD, Akio Munakata, MD, Yoshihiko

1 Watanabe, MD (Munakata Clinic, Mobara-City, Chiba); Ms. Yayoi Takanashi, Reiji Masaki,
2 NP, Tomohiko Inoue, MD, Shinnosuke Sugihara, MD, Kanako Nagaoka, MD and Hiroshi Kuji,
3 MD (Kameda Medical Center, Kamogawa-City, Chiba); Kenji Yamaguchi, MD (Awa Regional
4 Medical Center, Tateyama-City, Chiba); Ms. Miyuki Sato (Fukushima Medical University
5 Hospital, Fukushima-City, Fukushima).

6

7 **Funding:**

8 This study was supported by JSPS KAKENHI (grant numbers JP19KT0021 and JP24K14750).

9 **Authors' contributions:**

10 Research idea and study design: AK, MU, and NK; data acquisition: AK, RI, MU, YK, T. Toishi,
11 MM, TO, YM, and TS; data analysis/interpretation: AK, RI, MU, TS, and NK; statistical
12 analysis: MU, TS, and NK; supervision or mentorship: TO, TS, and NK. Each author
13 contributed important intellectual content during manuscript drafting or revision, agreed to
14 be personally accountable for the individual's contributions, and ensured that questions on
15 the accuracy or integrity of any portion of the work, even one in which the author was not
16 directly involved, were appropriately investigated and resolved, including documentation in
17 the literature, if appropriate.

18

19 **Conflict of interest statement:**

20 The RI received payments for speaking from Astellas Pharma, Inc., Novartis Pharma K.K., and
21 Otsuka Pharmaceuticals. T. Toida received consulting fees from Astellas Pharma Inc. and
22 payments and educational events from Torii Pharmaceutical Co., Ltd., Ono Pharmaceutical
23 Co., Ltd., Kyowa Kirin Co., Ltd., AstraZeneca K.K., and Nobelpharma Co., Ltd. T. Toishi

1 received payments for speaking and educational events from Otsuka Pharmaceuticals. YK
2 has ownership interest in Takeda Pharmaceutical Co., Ltd. MM received payments for
3 speaking and educational events from Astellas Pharma, Inc. and Baxter Co., Ltd. TS has
4 received payment for speaking and educational events from Astellas Pharma Inc.,
5 AstraZeneca K.K, Baxter Co., Ltd., Bayer Yakuhin., Ltd., Bristol-Myers Squibb Co., CureApp,
6 Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Janssen
7 Pharmaceutical K.K, Kaneka Medix Corp, Kissei Pharmaceutical Co., Ltd., Kowa Co., Ltd.,
8 Kyowa Kirin Co., Ltd, Mochida Pharmaceutical Co., Ltd., Nobelpharma Co., Ltd, Novartis
9 Pharma K.K., Novo Nordisk Pharma., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka
10 Pharmaceutical, Terumo Corp, and Torii Pharmaceutical Co., Ltd. NK received grants from
11 the Japan Society for the Promotion of Science, consulting fees from GlaxoSmithKline K.K.,
12 and payments for speaking and educational events from Taisho Pharmaceutical Co. Ltd., Eisai
13 Co. Ltd., UCB Japan K.K., and Selista Corporation. The remaining authors have no conflicts to
14 disclose.

15

16 **References:**

- 17 1. Dorans KS, et al. Associations of Anxiety during the COVID-19 Pandemic with Patient
18 Characteristics and Behaviors in CKD Patients: Findings from the Chronic Renal Insufficiency
19 Cohort (CRIC) Study. *Kidney360* 2022; **3**: 1341–9.
- 20 2. Natale P, et al. The Impact of the COVID-19 Pandemic on Patients With CKD:
21 Systematic Review of Qualitative Studies. *Am J Kidney Dis* 2023; **82**: 395–409.e1.
- 22 3. Schouten RW, et al. Anxiety Symptoms, Mortality, and Hospitalization in Patients
23 Receiving Maintenance Dialysis: A Cohort Study. *Am J Kidney Dis* 2019; **74**: 158–66.

- 1 4. Okan O, et al. Health literacy as a social vaccine in the COVID-19 pandemic. *Health*
2 *Promot Int* 2023; **38**: daab197.
- 3 5. Taylor DM, et al. A Systematic Review of the Prevalence and Associations of Limited
4 Health Literacy in CKD. *Clin J Am Soc Nephrol*. 2017; **12**: 1070–84.
- 5 6. Nutbeam D. Health literacy as a public health goal: a challenge for contemporary
6 health education and communication strategies into the 21st century. *Health Promot Int*
7 2000; **15**: 259–67.
- 8 7. Inanaga R, et al. Trust, Multidimensional Health Literacy, and Medication Adherence
9 among Patients Undergoing Long-Term Hemodialysis. *Clin J Am Soc Nephrol* 2024; **19**: 463–
10 71.
- 11 8. Yoon IJ, Lee SJ. Health Literacy and Anxiety Among Hemodialysis Patients During the
12 Coronavirus Disease Pandemic. *Psychol Res Behav Manag* 2023; **16**: 1051–61.
- 13 9. Wakashima K, et al. The Japanese version of the Fear of COVID-19 scale: Reliability,
14 validity, and relation to coping behavior. *PloS one* 2020; **15**: e0241958.
- 15 10. Ahorsu DK, Lin et al. The fear of COVID-19 scale: Development and initial validation.
16 *nt J Ment Health Addict* 2022; **20**: 1537–45.
- 17 11. Ishikawa H, Takeuchi T, Yano E. Measuring functional, communicative, and critical
18 health literacy among diabetic patients. *Diabetes care* 2008; **31**: 874–9.
- 19 12. Hemmelgarn BR, et al. Adapting the Charlson Comorbidity Index for use in patients
20 with ESRD. *Am J Kidney Dis* 2003; **42**: 125–32.

- 1 13. Kanakubo Y, et al. Association between person-centred care quality and advance
2 care planning participation in haemodialysis. *BMJ Suppor Palliat Care* 2024
3 <http://dx.doi.org/10.1136/spcare-2024-004831>
- 4 14. Austin PC, et al. Missing Data in Clinical Research: A Tutorial on Multiple Imputation.
5 *Can J Cardiol* 2021; **37**: 1322–31.
- 6 15. Shevlin M, et al. Anxiety, depression, traumatic stress and COVID-19-related anxiety
7 in the UK general population during the COVID-19 pandemic. *BJPsych Open* 2020; **6**: e125.
- 8 16. Bouwmans P, et al. Differences in mental health status during the COVID-19
9 pandemic between patients undergoing in-center hemodialysis and peritoneal dialysis. *J*
10 *Nephrol* 2023; **36**: 2037–46.
- 11 17. Hilbrands LB. The COVID-19 pandemic and mental health outcomes in CKD patients.
12 *Nephrol Dial Transplant* 2023; **38**: 2673–4.
- 13 18. Bonenkamp AA, et al. The Impact of COVID-19 on the mental health of dialysis
14 patients. *J Nephrol* 2021; **34**: 337–44.
- 15 19. Kuroda Y, Goto A, Koriyama C, Suzuki K. Association of health literacy with anxiety
16 about COVID-19 under an infectious disease pandemic in Japan. *Health Promot Int* 2023; **38**:
17 daac200.

1 **Tables + table legends:**

2 **Table 1. Patient characteristics† (N = 446)**

		Missing, n
Age, years	69.4 (63.0–78.0)	0
Women, n (%)	157 (35.2)	0
Kidney disease, n (%)		0
Diabetic nephropathy	166 (37.2)	
Chronic glomerulonephritis	102 (22.9)	
Nephrosclerosis	61 (13.7)	
Polycystic kidney disease	14 (3.1)	
Others	68 (15.3)	
Unknown	35 (7.9)	
Dialysis duration, year	5.8 (2.9-10.6)	0
Comorbidities, n (%)		
Cardiovascular disease	187 (42.3)	4
Depression	10 (2.2)	1
Diabetes	192 (43.3)	3
Malignancy	47 (10.6)	1
Leukaemia	2 (0.5)	1
Malignant lymphoma	5 (1.1)	1
Dementia	19 (4.3)	2
Chronic liver disease	25 (5.6)	1
Peptic ulcer	33 (7.4)	0
Chronic lung disease	11 (2.5)	3
Collagen disease	11 (2.5)	2
modified Charlson score, points	1.0 (0–2)	0
Smoking, n (%)		21
Never	232 (54.6)	
Ever	145 (34.1)	
Current	48 (11.3)	
Household income, n (%)		35
< 1,000,000 yen	37 (9.0)	
1,000,000– < 5,000,000 yen	291 (70.8)	
5,000,000– < 10,000,000 yen	69 (16.8)	
> 10,000,000 yen	14 (3.4)	
Education level, n (%)		19
Junior high school graduate or less	102 (23.9)	
High school graduate	263 (61.6)	
University/Graduate school graduate	57 (13.3)	
Others	5 (1.2)	
COVID-19 vaccination, n (%)		0
Unvaccinated	1 (0.2)	

Once	5 (1.1)	
Twice	9 (2.0)	
Thrice	431 (96.6)	
Functional HL, per 1-pt higher	3.2 (2.6–3.8)	14
Communicative HL, per 1-pt higher	2.8 (2.2–3.2)	24
Critical HL, per 1-pt higher	2.5 (2.0–3.0)	13

- 1 [†]Continuous variables are summarised as median (interquartile range). Categorical variables
2 are presented as frequencies and proportions (parentheses).
- 3 According to the "Comprehensive Survey of Living Conditions" conducted by the Ministry of
4 Health, Labour and Welfare in 2022, the percentages of household income < 1 million yen,
5 1–3 million yen, 3–5 million yen, 5–10 million yen, and >10 million yen were 7%, 28%, 23%,
6 30%, and 13%, respectively.

1 **Table 2. Associations of health literacy domains with covariates† (N = 446)**

	Functional HL		Communicative HL		Critical HL	
	mean difference, point estimate (95%CI)	P-value	mean difference, point estimate (95%CI)	P-value	mean difference, point estimate (95%CI)	P-value
Age, per 10-yr higher	-0.002 (-0.08 – 0.05)	0.610	-0.07 (-0.12 – -0.002)	0.012	-0.01 (-0.02 – -0.004)	0.001
Women vs. Men	-0.01 (-0.19 – 0.17)	0.904	0.06 (-0.09 – 0.22)	0.429	0.08 (-0.07 – 0.24)	0.303
Smoking						
Never	Reference		Reference		Reference	
Ever	0.09 (-0.09 – 0.27)	0.271	0.09 (-0.08 – 0.27)	0.287	0.01 (-0.16 – 0.18)	0.886
Current	-0.01 (-0.27 – 0.27)	0.271	-0.03 (-0.27 – 0.19)	0.764	0.03 (-0.18 – 0.25)	0.767
Household income						
< 1,000,000 yen	Reference		Reference		Reference	
1,000,000– < 5,000,000 yen	0.17 (-0.13 – 0.47)	0.266	0.02 (-0.23 – 0.28)	0.862	-0.03 (-0.27 – 0.20)	0.771
5,000,000– < 10,000,000 yen	0.15 (-0.20 – 0.50)	0.407	-0.06 (-0.35 – 0.24)	0.712	-0.12 (-0.40 – 0.16)	0.384
> 10,000,000 yen	0.28 (-0.21 – 0.78)	0.260	-0.06 (-0.53 – 0.41)	0.813	-0.05 (-0.53 – 0.43)	0.838
Education level						
Junior high school graduate or less	Reference		Reference		Reference	
High school graduate	0.37 (0.16 – 0.58)	< 0.001	0.17 (0.0004 – 0.34)	0.049	0.10 (-0.07 – 0.27)	0.242
University/Graduate school graduate	0.64 (0.39 – 0.89)	< 0.001	0.50 (0.27 – 0.74)	< 0.001	0.46 (0.21 – 0.71)	< 0.001
Others	0.87 (0.27 – 1.46)	0.004	0.63 (0.07 – 1.12)	0.030	0.58 (0.07 – 2.20)	0.027
Dialysis duration, per 1-yr higher	0.01 (0.002 – 0.02)	0.013	0.003 (-0.004 – 0.01)	0.389	0.003 (-0.004 – 0.01)	0.373
Modified Charlson score, per 1-pt higher	-0.06 (-0.11 – -0.02)	0.009	-0.05 (-0.08 – -0.01)	0.008	-0.04 (-0.07 – -0.006)	0.021
Depression	-0.15 (-0.64 – 0.33)	0.533	0.12 (-0.28 – 0.51)	0.565	0.35 (-0.04 – 0.74)	0.079

2 Values in bold indicate statistical significance. For each HL domain score, a general linear model was fitted with the inclusion of all the variables listed

3 above. We used a robust standard estimation method. HL, health literacy; CI, confidence interval.

1 **Table 3. Associations of COVID-19 fear score with health literacy and covariates† (N = 446)**

	Corresponding standardised ES	mean difference, point estimate (95%CI)	P-value
Functional HL, per 1-pt higher	-0.18	-0.99 (-1.72 – -0.26)	0.008
Communicative HL, per 1-pt higher	-0.10	-0.59 (-1.69 – 0.51)	0.291
Critical HL, per 1-pt higher	0.34	1.85 (0.74 – 2.97)	0.001
Age, per 10-yr higher	0.006	0.03 (-0.01 – 0.08)	0.160
Women vs. Men	0.37	1.98 (0.73 – 3.23)	0.002
Smoking			
Never		Reference	
Ever	-0.15	-0.79 (-2.06 – 0.47)	0.238
Current	-0.08	-0.42 (-2.22 – 1.39)	0.649
Household income			
< 1,000,000 yen		Reference	
1,000,000– < 5,000,000 yen	-0.25	-1.37 (-3.65 – 0.93)	0.233
5,000,000– < 10,000,000 yen	-0.56	-3.01 (-5.41 – -0.61)	0.014
> 10,000,000 yen	-0.61	-3.29 (-6.49 – 0.10)	0.043
Education level			
Junior high school graduate or less		Reference	
High school graduate	-0.11	-0.57 (-1.97 – 0.85)	0.420
University/Graduate school graduate	-0.30	-1.60 (-3.42 – 0.22)	0.084
Others	0.62	3.36 (-1.55 – 8.28)	0.179
Dialysis duration, per 1-yr higher	0.006	-0.03 (-0.04 – 0.10)	0.367
Modified Charlson score, per 1-pt higher	-0.02	-0.11 (-0.40 – 0.18)	0.450
Depression	0.07	0.39 (-3.03 – 3.81)	0.825

2 Values in bold indicate statistical significance. The general linear model was fitted with the
3 inclusion of all the variables listed above. We used a robust standard estimation method. To
4 calculate the corresponding standardised effect size (Cohen *d*), the point estimate was
5 divided by the SD of the COVID-19 fear scores to calculate the corresponding standardised
6 effect size (Cohen’s *d*). CI, confidence interval; ES, effect size; HL, health literacy.

1 **Figures + figure legends:**

2 **Figure 1. Comparison of group mean of COVID-19 fear scores**

3 Using the mean and standard deviation of fear scores for COVID-19 in the present study and
4 the corresponding values of the scores from 450 Japanese adults in April 2020 (i.e. at the
5 beginning of the COVID-19 outbreak), as reported in a development paper, these groups
6 were compared using an unpaired t-test. Error bars indicate 95% confidence intervals. The
7 mean difference for this population relative to the Japanese adults was -4.38 points (95%
8 confidence interval -5.11 – -3.65).

